نتایج جستجو برای: irinotecan

تعداد نتایج: 4284  

Journal: :Cancer research 1996
E Gupta A R Safa X Wang M J Ratain

The focus of this investigation was to modulate the pharmacokinetics of irinotecan and its metabolites, SN-38 and SN-38G, by possibly reducing biliary excretion, which in turn could lower irinotecan toxicity. We determined the effect of a known cholestatic agent, cyclosporin A (CsA), which is transported across the bile canalicular membrane by P-glycoprotein, on the biliary excretion of irinote...

Journal: :Molecular medicine reports 2010
Ryuji Ikeda Lee C Vermeulen Elim Lau Zhisheng Jiang Marcia Pomplun Jill M Kolesar

Irinotecan (CTP-11) is a topoisomerase I inhibitor used in the treatment of colorectal cancer and non-small cell lung cancer (NSCLC). Despite an initial response to therapy, resistance to irinotecan reduces its efficacy. We isolated irinotecan-resistant human NSCLC A549 cells, termed A549/CTP-11R cells. A549/CTP-11R cells were resistant to irinotecan, as well as paclitaxel, gemcitabine and carb...

Journal: :Molecular cancer therapeutics 2013
Thibault Mazard Annick Causse Joelle Simony Wilhem Leconet Nadia Vezzio-Vie Adeline Torro Marta Jarlier Alexandre Evrard Maguy Del Rio Eric Assenat Pierre Martineau Marc Ychou Bruno Robert Celine Gongora

Despite recent advances in the treatment of colorectal cancer (CRC), tumor resistance is a frequent cause of chemotherapy failure. Therefore, new treatment options are needed to improve survival of patients with irinotecan-refractory CRCs, particularly those bearing KRAS mutations that preclude the use of anti-EGFR therapies. In this study, we investigated whether sorafenib could reverse irinot...

2006
Elora Gupta Ahmad R. Safa Xiaolin Wang Mark J. Ratain

The locus of this investigation was to modulate the pharmacokinetics of irinotecan and its metabolites, SN-38 and SN-38G, by possibly reducing biliary excretion, which in turn could lower irinotecan toxicity. We de termined the effect of a known cholestatic agent, cyclosporin A (CsA), which is transported across the bile canalicular membrane by P-glycoprotein, on the biliary excretion of irinot...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2006
Seungwon Kim Christopher N Prichard Maher N Younes Yasemin D Yazici Samar A Jasser B Nebiyou Bekele Jeffrey N Myers

PURPOSE Anaplastic thyroid carcinoma (ATC) remains one of the most lethal known human cancers. Targeted molecular therapy with cetuximab, a monoclonal antibody against epidermal growth factor receptor, offers new treatment potentials for patient with ATC. Cetuximab has also been reported to have synergistic effects when combined with irinotecan, a topoisomerase inhibitor. Therefore, we hypothes...

Journal: :Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008
Alberto F Sobrero Joan Maurel Louis Fehrenbacher Werner Scheithauer Yousif A Abubakr Manfred P Lutz M Eugenia Vega-Villegas Cathy Eng Ernst U Steinhauer Jana Prausova Heinz-Josef Lenz Christophe Borg Gary Middleton Hendrik Kröning Gabriele Luppi Oliver Kisker Angela Zubel Christiane Langer Justin Kopit Howard A Burris

PURPOSE To determine whether adding cetuximab to irinotecan prolongs survival in patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine and oxaliplatin. PATIENTS AND METHODS This multicenter, open-label, phase III study randomly assigned 1,298 patients with epidermal growth factor receptor-expressing mCRC who had experienced first-line fluoropyrimidine and ...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 1998
H Shinohara J J Killion H Kuniyasu R Kumar I J Fidler

The induction of severe diarrhea limits the usefulness of the DNA topoisomerase I inhibitor irinotecan (CPT-11) in the treatment of advanced colon cancer. We investigated whether oral administration of the new synthetic bacterial lipopeptide, JBT 3002, encapsulated in phospholipid liposomes could prevent damage to the intestinal epithelium and lamina propria and thus allow for the parenteral ad...

2018
Liuting Yang Xiaoyue Jiang Han Yan Yingying Li Hongchao Zhen Bingmei Chang Seyed Kariminia Qin Li

BACKGROUND For patients with advanced gastric cancer (AGC), second-line chemotherapy regimen remains controversial. The efficacy and safety of irinotecan-containing doublet treatment and irinotecan monotherapy were compared in this systematic analysis. METHODS A search was conducted on EMBASE and Medline databases. All articles compared irinotecan-containing doublet to irinotecan as second-li...

Journal: :International journal of oncology 2016
Atsushi Ikai Motoki Watanabe Yoshihiro Sowa Mitsuo Kishimoto Akio Yanagisawa Hitoshi Fujiwara Eigo Otsuji Toshiyuki Sakai

Irinotecan has been used in the first-line treatment of metastatic colorectal cancer. However, no clear predictive marker of irinotecan efficacy has been identified. It is controversial whether the response to irinotecan could be predicted by the expression level of topoisomerase-I, a direct target of irinotecan. The present study aimed to identify a feasible predictive marker of irinotecan eff...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2007
Monica E Loghin Michael D Prados Patrick Wen Larry Junck Frank Lieberman Howard Fine Karen L Fink Minesh Metha John Kuhn Kathleen Lamborn Susan M Chang Timothy Cloughesy Lisa M DeAngelis Ian H Robins Kenneth D Aldape W K Alfred Yung

PURPOSE To determine the maximum tolerated dose of irinotecan when administrated with temozolomide every 28 days, in patients with recurrent malignant glioma who were also receiving CYP450 enzyme-inducing antiepileptic drugs (EIAED), and to characterize the pharmacokinetics of irinotecan and its metabolites. The study was also intended to assess whether temozolomide affects the conversion of ir...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید